Invitrocue releases Appendix 4C for quarter ended 31 December 2018

January 31, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, today released its Appendix 4C for the quarter ended 31 December 2018 (Reporting Period). In addition to the financial results as disclosed in the announcement, Invitrocue provides the following highlights of the company during the Reporting Period and the period immediately thereafter.

• Increasing number of patients using Onco-PDO^TM, now commercially available in Asia and Europe

• Appointed Dr Andreas Lindner to new role of CEO of Invitrocue Europe in preparation for commercial roll-out of Onco-PDO^TM in new markets in 2019
• New agreement signed with German laboratory partner to establish central lab in Europe

• Appointment of Assoc Professor Narayanan Gopalakrishna Iyer as Chairman of Clinical Advisory Board and Professor David Waugh as advisor to establish network in Australia
• New collaboration with Professor Zeng Yi of Shanghai Institute of Biochemistry and Cell Biology to develop new breast cancer models for Onco-PDO^TM
• Conducted inaugural key opinion leader Onco-PDO^TM educational seminar

2018 marked a year of great progress for Invitrocue as we focused on establishing a strong commercial pathway for Onco-PDO^TM in our key geographies of Asia and Europe. Commercial sales of the test are underway in Asia, using our Singapore laboratory as a central testing lab in the region. During the period, we continued to receive an increasing number of patient samples from across Asia, including our first patient sample from Malaysia.

The appointment of Dr. Andreas Lindner to the newly created role of Chief Executive Officer of our European operations marked an important milestone for the company in relation to our global commercialisation plans. Dr. Lindner has a strong track record in building successful medical organisations. Post period end, we announced the signing of an agreement to establish our European laboratory facilities in Munich, Germany. The lab is now fully operational and accepting commercial Onco-PDO^TM samples from Germany and other European countries, including Spain and Austria.

Working closely with our team of scientific advisors, we are expanding Onco-PDO^TM’s cancer indication menu by co-developing models and protocols for additional cancer types to the four indications we currently offer testing in. We welcomed Professor David Waugh to the Advisory Board during the period and look forward to working with him in Australia to raise awareness of Onco-PDO^TMand address the growing burden of cancer in this important market. Assoc Professor Narayanan Gopalakrishna Iyer was appointed to the role of Chair of the Medical Advisory Board and we have already benefitted from the valuable insights he shares from his active involvement in oncology research programs.

An ongoing commitment to the education of physicians and patients is a cornerstone to our commercial strategy as we ramp-up the international commercialisation of Onco-PDO^TM. In October we hosted our inaugural educational summit in Germany, bringing together international experts on oncology, precision medicine, and biochemistry from leading global institutes, cancer centres and universities. In 2019, we will continue to actively engage key opinion leaders and broaden our summit series to Asia to accelerate the commercial uptake of Onco-PDO^TM.

Commenting on the results, Dr Steven Fang, Executive Chairman, Invitrocue, said: “2018 marked a breakthrough year for Invitrocue, the year in which we generated our first commercial revenues for Onco-PDO^TM. We are now in a strong position to address one of the key global concerns for treating cancer by providing the missing data point to physicians and patients that has the potential to transform treatment pathways and improve patient outcomes. “In 2019 and beyond, our focus is to drive widespread awareness and adoption of Onco-PDOTM as a key tool in evidence-based decision making. With the support and guidance of our advisory board, weare optimising protocols to expand the indication menu and generating new clinical data to further validate our approach. We look forward with confidence to working with our partners as we broaden the international availability of Onco-PDO in new markets and through new partnerships.”

Conference call details

There will be a conference call for investors and analysts on Monday, 11 February, hosted by Executive Chairman, Dr Steven Fang. If you wish to submit questions in advance please direct them to Invitrocue@spurwingcomms.com.

Monday, 11 February 2019

18:00 Sydney, +61 (0) 2 8015 2088

15:00 Singapore, +65 3158 7288

08:00 Munich, +49 (0) 30 3080 6188

07:00 London, +44 (0) 20 3051 2874

Access Code: 677 398 835

To join the call from PC, Mac, Linux, iOS or Android click here.

Additional international numbers available here

- ENDS -

For more information contact:

Martin D. Bach, VP Operations

T: +65 6560 0497

martind.bach@invitrocue.com

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine). Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators. Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com